- Home
- EVMN vs BBNX Comparison
EVMN vs BBNX Comparison
Compare EVMN & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVMN | BBNX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | 48 | 423 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.8M | 493.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EVMN | BBNX |
|---|---|---|
| Price | $11.40 | $16.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $43.88 | $23.80 |
| AVG Volume (30 Days) | ★ 1.4M | 977.2K |
| Earning Date | 06-11-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.15 | $8.80 |
| 52 Week High | $33.20 | $32.71 |
Technical Indicators
Market Signals| Indicator | EVMN | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 32.78 | 53.29 |
| Support Level | N/A | $16.02 |
| Resistance Level | $21.21 | $32.52 |
| Average True Range (ATR) | 1.06 | 1.15 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 9.46 | 25.79 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.